Abstract Number: 1923 • 2016 ACR/ARHP Annual Meeting
Activated Partial Thromboplastin Time Reflects Disease Activity in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of systemic vasculitides associated with ANCA specific for myeloperoxidase (MPO) or proteinase-3 (PR3), and includes…Abstract Number: 1947 • 2016 ACR/ARHP Annual Meeting
Ocular Manifestations of ANCA-Associated Vasculitis
Background/Purpose: Ocular involvement in ANCA-associated vasculitis (AAV) can cause substantial morbidity. We aimed to characterize patterns of ocular involvement in AAV and their response to…Abstract Number: 1925 • 2016 ACR/ARHP Annual Meeting
Interest of Procalcitonin for the Follow-up of ANCA-Associated Vasculitis: Data from a Cohort of 99 Patients
Background/Purpose: The prognosis of the ANCA associated vasculitis (AAV) has improved with the new immunosuppressive treatments but infectious complications remain frequent. Procalcitonin (PCT) is…Abstract Number: 1949 • 2016 ACR/ARHP Annual Meeting
Presentation, Prognosis and Clinical-Pathological Correlations of Cutaneous Manifestations in ANCA-Associated Vasculitides
Background/Purpose: Cutaneous involvement is frequent during ANCA-associated vasculitis (AAV) and can reveal the disease. However, no large study on presentation and clinical-pathological correlations is available.…Abstract Number: 1926 • 2016 ACR/ARHP Annual Meeting
Indications for Testing and Diagnostic Outcome in Patients with Positive ANCA at a Canadian Tertiary Care Centre
Background/Purpose: Anti-neutrophil cytoplasmic antibodies (ANCA) are a hallmark of a subset of small vasculitides collectively termed ANCA-associated vasculitis (AAV). With widespread availability of ANCA testing,…Abstract Number: 1950 • 2016 ACR/ARHP Annual Meeting
ANCA-Associated Vasculitides and IgG4-Related Disease: An Overlapping Syndrome? a European Observational Study of 18 Patients
Background/Purpose: Atypical manifestations have been described in patients with antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitides (AAV), such as periaortic fibrosis, pachymeningitis and orbital mass. Because these…Abstract Number: 1929 • 2016 ACR/ARHP Annual Meeting
Comparison of Two Different ANCA Iif Methods with EIA and Disease Phenotype
Background/Purpose: ANCAs are used as diagnostic markers in patients with autoimmune vasculitis such as Granulomatosis with polyangitis (GPA), Microscopic polyangitis (MPA), and Eosinophilic granulomatosis with…Abstract Number: 1951 • 2016 ACR/ARHP Annual Meeting
Phenotypic and Functional Perturbations of Peripheral B and T Lymphocytes in Granulomatosis with Polyangiitis and Microscopic Polyangiitis
Background/Purpose: Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are both anti-neutrophil cytoplasm antibodies (ANCA)-associated vasculitides (AAV), but differ in clinical presentation. Anti-myeloperoxydase (MPO)-ANCA were…Abstract Number: 1930 • 2016 ACR/ARHP Annual Meeting
Factors Associated with Glucocorticoid Exposure in ANCA-Associated Vasculitis
Background/Purpose: Factors associated with cumulative glucocorticoid exposure in granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) have not previously been described. We examined the association…Abstract Number: 1952 • 2016 ACR/ARHP Annual Meeting
Kv1.3 Channel Blockade Modulates the Effector Function of B Cells in Granulomatosis with Polyangiitis
Background/Purpose: Granulomatosis with polyangiitis (GPA) patients are often treated with immunesuppressives or B cell depleting therapy. While B cells are involved in GPA pathogenesis as…Abstract Number: 1931 • 2016 ACR/ARHP Annual Meeting
MRI Findings in Granulomatosis with Polyangiitis: Pachymeningitis and Implications in Quality of Life
Background/Purpose: The frequency of CNS involvement in granulomatosis with polyangiitis (GPA) is uncommon (4-18%). Among them, pachymeningitis (PM) has been reported in 0.6-8%. Improvement of…Abstract Number: 1955 • 2016 ACR/ARHP Annual Meeting
Rituximab Versus Azathioprine to Maintain Remission of ANCA-Associated Vasculitides (MAINRITSAN): Follow-up at 60 Months
Background/Purpose: The previously reported prospective, randomizedÐcontrolled MAINRITSAN trial compared rituximab (RTX) to azathioprine (AZA) for maintenance of ANCA-associated vasculitis (AAV) remissions obtained with a combined…Abstract Number: 1933 • 2016 ACR/ARHP Annual Meeting
M2 Macrophage Is the Predominant Phenotype in Airways Inflammatory Lesions in Patients with Granulomatosis with Polyangiitis
Background/Purpose: Macrophages may present two main phenotypes indicated as M1 and M2 under different stimuli. M1- and M2-macrophages have divergent functions that range from enhancement…Abstract Number: 2078 • 2016 ACR/ARHP Annual Meeting
Global Ethnic and Geographic Differences in the Clinical Features of ANCA-Associated Vasculitis
Background/Purpose: There are few data on clinical profiles of ANCA-associated vasculitis (AAV) and or ANCA specificity in different ethnic populations. This study examined differences in…Abstract Number: 1936 • 2016 ACR/ARHP Annual Meeting
Clinical Characteristics of Inflammatory Eye Disease in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Cohort Study
Clinical Characteristics of Inflammatory Eye Disease in Patients with Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Cohort Study Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 20
- Next Page »